Table 2.
Quality of life in patients with Non-Hodgkin Lymphoma (NHL) with and without Human Immunodeficiency Virus Infection (HIV) as measured by the Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) and Functional Assessment of Cancer Therapy-General (FACT-G)
| HIV-NHL (N = 50) mean (SD) | NHL (N = 50) mean (SD) | p by GLMa comparing mean in HIV-infected NHL versus uninfected NHL | p by MANOVAb comparing mean in HIV-infected NHL versus uninfected NHL | Reported cancer patient normc (N = 2,236) | |
|---|---|---|---|---|---|
| Total | 68.4 (15.9) | 81.9 (16.1) | .0001 | .0001 | 80.9 (17.0) |
| Emotional well-being | 17.3 (4.1) | 18.9 (3.8) | .05 | 0.19 | 18.7 (4.5) |
| Functional well-being | 14.6 (6.2) | 18.8 (7.0) | .002 | .0001 | 18.9 (6.8) |
| Physical well-being | 18.0 (6.7) | 22.3 (5.9) | .001 | .002 | 21.3 (6.0) |
| Social well-being | 18.5 (6.5) | 21.9 (5.1) | .005 | .03 | 22.1 (5.3) |
aGeneral linear model
bMultivariate analysis of variance model includes nodal status and histologic, insurance and income categories
cNormative data presented for comparison [15]